NCT07108699 - Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

September 30, 2026

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

HSK39004 Dry Powder Inhaler-0.75mg

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day

DRUG

HSK39004 Dry Powder Inhaler-1.5mg

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day

DRUG

HSK39004 Dry Powder Inhaler Simulant

HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily

Trial Locations (1)

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY